Medication Guides Nancy M. Ostrove, Ph.D. Division of Drug Marketing, Advertising, and Communications.

Slides:



Advertisements
Similar presentations
Drug Information for Consumers and Healthcare Professionals Food and Drug Law Institute Annual Meeting Alan Goldhammer, PhD Associate VP Regulatory Affairs.
Advertisements

Safety in the Pharmacy Health Science Technology.
An Overview of Direct-to-Consumer Prescription Drug Promotion Nancy M. Ostrove, Ph.D. Risk Communication Advisory Committee May 15, 2008.
Management of Drug Formulary Dimitry Gotlinsky Western University Managed Care Clerkship ProPharma Pharmaceutical Consultants, Inc. 06/16/06.
Financial Statements Audit
© 2009 South-Western, Cengage LearningMARKETING 1 Chapter 2 SOCIALLY RESPONSIVE MARKETING 2-1The Impact of Marketing 2-2Criticisms of Marketing 2-3Increasing.
RAC Study Group Chapter 16
GOOD PHARMACY PRACTICE
FEDERAL REGULATIONS OF MEDICATIONS Food, Drug and Cosmetic Act Protect consumers from adulterated and misbranded foods, drugs, cosmetics, or devices.
Objectives Why we need DHCPL Situations that call for a DHCPL Definitions DHCPL itself–content, presentation, process Target audience Current and future.
Promoting Excellence in Family Medicine Enabling Patients to Access Electronic Health Records Guidance for Health Professionals.
1 Alvimopan RiskMAP Joyce Weaver, Pharm.D., BCPS Office of Surveillance and Epidemiology.
Assessing the Impact of a Toll-Free Number for Reporting Side Effects in Direct-to-Consumer Television Ads: Proposed Study Design Kathryn J. Aikin, Ph.D.
Mrs. Brandi Robinson Office of New Animal Drug Evaluation Center for Veterinary Medicine Regulating Animal Drugs.
April 8, 2005FDLI Annual Conference 1 Labeling Prescription Drugs for Physicians and Consumers (FDA Perspective) Paul J. Seligman, MD, MPH Director, Office.
Prescription Drug Information for Patients: History
Drug and Product Labeling
Unlicensed Medicines in Paediatrics Is there a problem ? Scottish Neonatal and Paediatric Pharmacist Group National Paediatric Pre- Registration Pharmacist.
Downstream Use of Structured Product Labeling Thomas R. Bizzaro, R.Ph. Vice President, Health policy and Industry Relations SPL/DailyMed Jamboree Workshop.
A substance used in the diagnosis, treatment, or prevention of a disease or as a component of a medication A substance used in the diagnosis, treatment,
Responsibilities and Principles of Drug Administration
When do I need an IND ? FDA Guidance for Industry – Investigation New Drug Applications (INDs) - Determining Whether Human Research Studies Can Be Conducted.
Slide 1 Long-Term Care (LTC) Collaborative PIP: Medication Review Tuesday, October 29, 2013 Presenter: Christi Melendez, RN, CPHQ Associate Director, PIP.
Drug Submissions: Review Process Agnes V. Klein, MD Biologics and Genetic Therapies Directorate February, 2003 www/hc-sc.gc.ca/hpb-dgps/therapeut.
Chapter 21 MARKETING - SOCIALLY RESPONSIBLE 1The Impact of Marketing 2Criticisms of Marketing 3Increasing Social Responsibility.
© 2009 South-Western, Cengage LearningMARKETING 1 Chapter 2 SOCIALLY RESPONSIVE MARKETING 2-1The Impact of Marketing 2-2Criticisms of Marketing 2-3Increasing.
FDA Risk Management Workshop: Concept Paper: Risk Management Programs April 10, 2003 Gary C. Stein, Ph.D. Director of Federal Regulatory Affairs American.
Key Compliance Risks in Clinical Trials Kathleen Meriwether Principal, ERNST & YOUNG, LLP Fraud Investigation & Dispute Services.
1 PhRMA Guiding Principles - DTC About Prescription Medicines.
ACCESS TO MEDICINES - POLICY AND ISSUES
2.2 Acquisition Methodology. “Acquisition methodology” – the processes employed and the means used to solicit, request, or invite offers that will normally.
Using Medicines Safely (2:50) Click here to launch video Click here to download print activity.
DIVISION OF REPRODUCTIVE AND UROLOGIC PRODUCTS Physician Labeling Rule Lisa Soule, M.D.
DODAC and DSaRM Advisory Committee August 1, 2007 Pregnancy Registry and Root Cause Analysis Cynthia Kornegay, Ph.D. Division of Drug Risk Evaluation Office.
History of Pediatric Labeling
Prof. Moustafa M. Mohamed Vice dean Dr. Safa Ahmed El-askary Faculty of Allied Medical Science Pharos University in Alexandria Development and Regulation.
2 NCPA’s Perspective on CMI, MedGuides and PPI February 26, 2009 before the Public Advisory Committee, FDA Tony Lee, Esq. Director of Public Policy
Research Needs to Support FDA Risk Communication Nancy M. Ostrove, Ph.D. Director for Risk Communication May 1, 2009.
The Commission for Social Care Inspection. Before we look at the content of the report, I feel that it is pertinent to look at who the Commission for.
July 15, Postmarketing Safety Evaluation of Approved Drugs and Risk Management Victor F. C. Raczkowski, MD, MS Director, Office of Drug Safety July.
1 DRAFT SLIDES FOR NDA ADVISORY COMMITTEE PRESENTATIONS.
History of FDA Consumer Information About Prescription Drugs Thomas J. McGinnis, R.Ph. July 17, 2002.
Suzanne Sechen, Ph.D. Leader, Ruminant Drugs Team Division of Production Drugs Office of New Animal Drug Evaluation, CVM Labeling Issues.
FDA Draft Guidance Good Reprint Practices for the Distribution of Medical Journal Articles and Medical or Scientific Reference Publications on Unapproved.
Abuse-Deterrent Opioids: FDA’s Role and Emerging Challenges Jeanne Ireland Principal, Ireland Strategies, LLC 2015 CWAG Annual Meeting.
Given the progress that continues to be made in society’s battle against disease, patients are seeking more information about medical problems and potential.
27 June 2000Victor F. C. Raczkowski, M.D.1 Risk-Management Options Victor F. C. Raczkowski, M.D., M.S. Gastrointestinal Drugs Advisory Committee 27 June.
Informed Consent Presented by Marian Serge, RN. Goals Informed consent process and form Title 38 CFR , Common Rule required elements and additional.
Complaint Handling Medical Device Reporting May 19, 2016 Rita Harden, Director Customer Relations & Regulatory Reporting.
A substance used in the diagnosis, treatment, or prevention of a disease or as a component of a medication recognized or defined by the U.S. Food, Drug,
Storage, Labeling, Controlled Medications Guidance Training CFR § (b)(2)(3)(d)(e) F431.
Clinical Trials.
Off-label Use.
Safety in the Pharmacy.
Division of Cardiovascular Devices
Copyright © 2016 by Mosby, an imprint of Elsevier Inc.
Strategies to Reduce Antibiotic Resistance and to Improve Infection Control Robin Oliver, M.D., CPE.
Reasonable Assurance of Safety and Effectiveness: An FDA Division of Cardiovascular Devices Perspective Bram Zuckerman, MD, FACC Director, FDA Division.
Presenter: Christi Melendez, RN, CPHQ
Using Medicines Safely (2:50)
Medical Device Regulatory Essentials: An FDA Division of Cardiovascular Devices Perspective Bram Zuckerman, MD, FACC Director, FDA Division of Cardiovascular.
The Nursing Process and Pharmacology Jeanelle F. Jimenez RN, BSN, CCRN
Labeling and Electronic Initiatives
National Pharmacy Practice Standards the Regulatory Role
Black Box Warning What You Need To Know.
Implementation Considerations
Participants’ Rights Participants of clinical trials have rights, and they are protected under law when participating in clinical trials. The informed.
Issues on Dispensing Dr Percy Mahlathi.
Using Medicines Safely (2:50)
Part II Objectives Describe how policies and procedures are used
Presentation transcript:

Medication Guides Nancy M. Ostrove, Ph.D. Division of Drug Marketing, Advertising, and Communications

Patient Rx Drug Information: Independently Produced u Supplied to pharmacies by information providers not affiliated with drug sponsors –private sector program u Computer-generated at point of purchase u Fairly wide distribution u Quality of information variable –recent assessment showed improvement needed, especially in risk disclosure

Patient Rx Drug Information: Mandated by Specific Regulations u Sponsor drafts and FDA approves u Different regulations -- different format and content requirements u Required to be distributed to patients –questions remain about whether distribution requirement is being achieved u Oral Contraceptives u Estrogens

Patient Rx Drug Information: Voluntary Patient Labeling u Sponsor drafts and FDA approves u No uniformity in format or content u No clear agreement whether distribution is required u Anecdotal evidence indicates that actual distribution is spotty, especially when not packaged in unit-dose containers

A New Type of Patient Rx Labeling: Medication Guides u Sponsor drafts and FDA approves u Non product specific regulation –designed for outpatient products that pose a “serious and significant public health concern” –necessary for safe and effective use by patients u On average, 5-10 products annually u Requires distribution

Triggering Circumstances u Could help prevent serious adverse effects u When patient needs to know of serious risks, relative to benefits, that might affect decision to use or continue use u When drug is important to health, and patient adherence to directions is critical to effectiveness

Medication Guide Requirements u Written in nontechnical, understandable language u Not promotional in tone or content u Scientifically accurate u Based on and consistent with professional labeling –language need not be identical to professional labeling

Medication Guide Requirements u Specific and comprehensive u At least 10 point minimum type size u Legible and clearly presented –appropriate use of highlighting techniques (bolding, underlining, other) to emphasize specific portions of text

Medication Guide Headings u What is the most important information I should know about... ? –description of the public health concern that creates the Medication Guide need u What is... ? –can include discussion of disease and benefits of treating condition u Who should not take...? –contraindications and what to do if any apply

Medication Guide Headings u How should I take...? –instructions for proper use u What should I avoid while taking...? –specific, important instructions to ensure proper use (activities, substances to avoid; risks to mothers, fetuses, nursing infants, children, etc.) u What are the possible or reasonably likely side effects of...?

Distribution is Required u Manufacturer responsible for ensuring distribution by either –providing enough to dispensers to give one to each patient, or –providing “means to produce” enough u Distributors responsible for passing on u Notation on container label that Medication Guide needs to be given out u Authorized dispenser required to give out

Exemptions/Deferrals u FDA can exempt applicant from any requirement except consistency with labeling and title (Medication Guide) u Prescriber can direct dispenser to withhold –but, patient can override withhold request

Conclusions u Medication Guides are for products posing a serious and significant public health concern u Medication Guides provide a uniform format and content to facilitate finding information u Medication Guides are required to be distributed to patients